Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Canadian government is inviting stakeholder feedback on proposed changes to address the current limitations Health Canada faces with regard to what information it can require from medical device sponsors once their products are approved for sale.
The proposed changes would introduce new obligations for manufacturers to submit annual reports and other information to the government department.
Compliance with the new requirements is expected to result in an annual cost burden of CAD943,950 ($716,601) over a 10-year period for the medtech industry. The government says, however, that this cost "would be offset by a number of qualitative benefits that would increase postmarket surveillance of medical devices and remove unnecessary burden to industry."
The proposed regulatory changes, when finalized, would make it necessary for manufacturers to:
In addition, the Canadian proposal includes provisions to change the reference to the International Organisation for Standardization (ISO) standard for quality systems management of medical devices, (included in the Canadian Medical Device Regulation) to an ambulatory reference.
The government said industry, in survey responses, had expressed support for the proposal to include an ambulatory reference to the latest ISO 13485 standard as this would facilitate international harmonization and allow industry to use a single audit standard in all markets. "This will improve certainty for manufacturers and avoid potential delay in medical devices being brought to the Canadian market. It will also eliminate the need for a regulatory amendment each time the international standard changes," the government added.
The proposed changes would allow Health Canada to receive more targeted and timely safety information on devices being marketed in foreign jurisdictions and in Canada.
At present, incidents occurring outside Canada only have to be reported if the regulatory agency of the country in which the incident occurred asks the manufacturer to take corrective action or if the manufacturer decides on its own to undertake such corrective action.
There is also no clarity on when this information must be submitted. The current Canadian regulations state that the preliminary report must be submitted "as soon as possible" instead of specifying a timeline, and there are no such criteria for submitting the final report. Moreover, the information submitted by manufacturers or importers focuses on the incident rather than the actions taken in response to the incident.
The government proposes that medical device license holders and importers of class II, III and IV products should set up systems to monitor safety-related information in relevant foreign jurisdictions, such as risk communications, labeling changes, recalls, reassessments and suspensions/revocations of device licenses. The license holders/importers would be expected to notify Health Canada within 72 hours of receiving safety-related information.
The government explained that this would allow Health Canada to get more targeted and pertinent information about actions taken in other countries. This is particularly important for actions that are typically not made public, such as reassessments, and are therefore less likely to come to the department's attention.
Comments on the proposed regulatory changes will be accepted until 26 August. The proposal forms part of government's ongoing action plan to improve the safety of medical devices, which was launched last December. (Also see "Manufacturers Support Health Canada Device Safety Plan, But Clinics May Adjust More Slowly" - Medtech Insight, 10 Jan, 2019.)
Medtech Insight: global medical technology news & analysis
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.
Topics FDA
Medtech Insight: global medical technology news & analysis
By Marion Webb
Amy Abernethy, FDA's principal deputy commissioner, sat down with Medtech Insight during CES 2020 to discuss the agency's progress on the Technology Modernization Action Plan, the pre-certification program for digital health products, and the FDA's plans for 2020.
Topics Digital Health FDA
Medtech Insight: global medical technology news & analysis
RTI Surgical, a surgical implants company, hired a global spine president and an original equipment manufacturer products president; Guerbet, a maker of medical-imaging products, promoted its chief commercial officer to CEO; and more.
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
